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Electroconvulsive therapy (ECT) is recommended for patients with psychotic disorders that do not respond to 
medication. Usually, many psychotropic medications have teratogenic effects on the fetus. ECT seems to be a 
relatively safe and effective treatment during pregnancy. We report here on a 33-year-old primigravida patient in her 
third trimester receiving ECT. (Korean J Anesthesiol 2011; 60: 217-220)
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    Electroconvulsive therapy (ECT) is recommended for patients 
with bipolar disorder who do not respond to medications [1]. 
It is safe and its efficacy has been well-established. Moreover, 
many psychotropic medications are known to have teratogenic 
effects on the fetus, and therefore ECT seems to be a relatively 
safe and effective choice of treatment in pregnant patients 
[2]. We experienced a pregnant patient in her third trimester 
receiving ECT and describe the results.
Case Report
    A 33-year-old primigravida at 28 weeks of gestation was 
admitted to a Psychiatric Department because of irritability, 
insomnia, and poor oral intake. She was not as talkative as she 
used to be and became paranoid. These symptoms started 
approximately 2 weeks prior to admission. The patient was 
diagnosed with schizophrenia 15 years ago. Since then she 
has been hospitalized five times with psychotic symptoms. 
The patient had been taking 3 mg of risperidone, 2 mg of 
benztropine, 10 mg of zolpidem, 25 mg of trazodone, and 25 mg 
of quetiapine everyday prior to admission.
    She was diagnosed as having a bipolar disorder with 
depressive episode and olanzapine 5 mg/day was administered 
additionally. Psychiatric examination revealed lack of self-care, 
and decreased psychomotor activity. Physical and neurological 
examinations were within normal limit.
    Electroconvulsive therapy was recommended and informed 
consent was obtained from her and her family. The obstetrician 
diagnosed her as 28
+1 weeks of pregnancy. The fetus was 
small for gestational age (0.77 kg estimated fetal body weight), 218 www.ekja.org
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but the location of placenta, amount of amniotic fluid and 
fetal heart rate were reported within the normal range. No 
other abnormality in her obstetric ultrasound was observed. 
Laboratory tests including CBC, and chemical test and 
electrocephalogram were within normal limit, except for 
hypoalbuminemia with an albumin level of 2.5 g/dl. There was 
no sign of premature labor and the pregnancy was uneventful.
    The patient was scheduled to undergo ECT seven times 
during 2 weeks. The electrocardiography, pulse oximetry and 
noninvasive blood pressure were measured during every ECT 
application. The fetal heart rate and uterine contractility were 
monitored by ultrasound during ECT and recovery periods. The 
patient also had a pad under the right side hip for left uterine 
displacement.
    Initial vital signs were stable, blood pressure was 100-
120/60-80 mmHg, heart rate was 80-90 bpm and oxygen 
saturation was 97-100% on room air.
    Anesthesia was induced with thiopental (4 mg/kg) without 
inhalation of any volatile anesthetics and muscle relaxation was 
obtained by succinylcholine (1 mg/kg) with Sellick’s maneuver. 
The patient was ventilated manually with 100% oxygen 3 L/
min using a face mask. Electrical stimulation was provided with 
a charge of 168 mC and the seizure duration was 75 second. 
Fetal heart rate was 140-160 bpm, and regarded as normal 
variability during ECT. After ECT, the patient stayed in recovery 
room for an hour to monitor both the mother and fetus. One 
hour after the first session of ECT, we noticed an abnormal 
movement in the patient’s abdomen. Fetal ultrasound was 
performed and regular uterine contraction was found. Fetal 
heart rate was 120-160 bpm. It was regarded as preterm labor, 
so we administered 50 mg of ritodrine mixed with 5% dextrose 
500 ml. Two hours later, the uterine contraction disappeared in 
the recovery room. After the patient’s state improved to normal, 
she was moved to the general ward.
    The patient underwent another six sessions of ECT. The 
electrical stimulations in the second, third and fourth sessions 
were 172 mC and seizure durations were 45 sec, 27 sec, and 
20 sec. The electrical stimulation in fifth, sixth and seventh 
sessions was 288 mC, and seizure durations were 45 sec, 30 
sec, and 34 sec. After the sixth session, psychiatric symptoms 
were improved markedly, and two weeks later, the patient was 
discharged with 7.5 mg/day of olanzapine.
    Three weeks after discharge, the patient was readmitted with 
the recurred psychiatric symptoms, and emergency cesarean 
section was performed. She was delivered of a 35
+4 weeks old 
premature baby weighing 1,940 g. The baby was diagnosed with 
hyaline membrane disease and congenital hypertrophic pyloric 
stenosis. He received ventilatory care for 7 days with surfactant 
treatment, and two month later he was operated on with the 
pyloromyotomy procedure.
Discussion
    About 7% of women of childbearing age suffer from acute 
symptoms of moderate to severe mental illness, or have 
recently experienced an episode requiring drug treatment [3]. 
Psychotropic medications are the first choice in treatment of 
mood disorder with psychotic features occurring in pregnant 
women [4]. But the psychotropics most commonly used for 
treating bipolar disorder are known to have adverse effects 
when used during pregnancy and breastfeeding periods [5].
    ECT is a nonpharmacologic biological treatment which 
has been shown to be a highly effective treatment option, 
especially for depression, and also for psychotic manifestation 
of schizophrenia [1]. In view of its efficacy and speed of action, 
ECT may be a first-line treatment for life-threatening depression 
and a second line treatment for patients with major depressive 
disorders who do not respond or respond incompletely to 
antidepressant drugs [1].
    ECT is now performed under general anesthesia. Guidelines 
by the American Psychiatric Association stated that anesthesia 
for ECT should be administered by a specially trained 
anesthesiologist, and the anesthesiologists should have 
overall responsibility, not only for anesthesia itself, but also for 
cardiopulmonary management and emergency care [6].
    To optimize the anesthetic management of patients 
undergoing ECT, it is important to understand the physiologic 
responses to the electrical stimulus, the effect of anesthetic 
drugs on the ECT response, and the pharmacologic effects of 
the drugs used to attenuate side effects related to ECT [7].
    Hemodynamic responses that occur during the ECT consist 
of generalized autonomic nervous system stimulation [7]. 
As the electrical current is delivered, the parasympathetic 
nervous system stimulation results in bradycardia, or rarely, 
asystole. Shortly thereafter, the sympathetic nervous system 
is stimulated, which usually causes tachycardia, hypertension 
lasting 5 minutes or longer, and may lead to arrhythmias [7,8]. 
Increased catecholamine blood level also can affect the uterus 
[9]. Vasoconstriction from catecholamine action decreases 
blood flow to the uterus and placenta with potential hypoxemia 
of the fetus. Usually, transient hypoxemia is tolerable. However, 
fetal bradycardia can occur if there are preexisting conditions 
such as chronic hypertension, or diabetes which tend to 
compromise uteroplacental circulation [9]. In this patient, 
transient hypertension (160-180/100-120 mmHg) and 
tachycardia (130-140 bpm) occurred during seizure activity, 
but fetal heart rate was maintained (140-160 bpm) during that 
period.
    The efficacy of ECT in alleviating acute depression is 
dependent on the duration of the induced seizure. EEG seizure 
activity lasting from 25 to 50 seconds is alleged to produce 219 www.ekja.org
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the optimal antidepressant response. Patients experiencing 
seizure duration of shorter than 15 seconds or longer than 
120 seconds achieve a less favorable response to ECT. Since 
many of the anesthetic drugs used for ECT have anticonvulsant 
properties, they would be expected to decrease the duration of 
ECT-induced seizure activity in a dose-dependent manner [7]. 
Methohexital is considered the “gold standard” in anesthetics 
for ECT [6,7]. It does not affect ECT seizure duration. 
Thiopental sodium can be an alternative barbiturate although 
it decreases seizure duration. Propofol has been used in many 
reports, because systemic cerebrovascular and hemodynamic 
changes under propofol anesthesia are more stable than 
under barbiturate anesthesia [8,10]. Volatile anesthetics such 
as sevoflurane can also be used in ECT. However, its time-
consuming induction, depression of seizure duration, and the 
requirement of an anesthesia machine make this technique 
impractical, except for women requiring ECT in the late 
stages of pregnancy, when it may reduce post-ECT uterine 
contractions [7,10]. Succinylcholine is the most commonly used 
muscle relaxant in ECT because of its short action duration. 
In this case, anesthesia was induced with thiopental sodium 
and succinylcholine. EEG seizure durations lasted for 20-75 
seconds, and the psychotic symptoms improved.
    Benabarre et al. [11] suggests that ECT minimize the risk for 
both mother and fetus. However, studies on the use of ECT 
during pregnancy, which is effective and appears to be safe, 
are limited [12]. Anderson and Reti [12] reviewed 339 cases 
on the use of electroconvulsive therapy during pregnancy 
from 1941 to 2007. It seems that ECT is an effective treatment 
for severe mental illness during pregnancy and that the risks 
to fetus and mother are low. But there were 20 maternal 
complications reported and 18 were likely related to ECT such 
as uterine contraction and/or preterm labor, vaginal bleeding, 
miscarriage, status epilepticus, hematuria, abdominal pain, 
and placental abruption. Fetal adverse events also reported 25 
cases, which included fetal death, transient fetal bradycardia 
and/or decelerations, club foot, prematurity, congenital blind-
ness, aorta coarctation, cortical infarcts, VATER syndrome and 
mental retardation. Of the 11 reported fetal deaths, only one 
was believed to be the direct result of ECT, which followed an 
episode of status epilepticus in the mother secondary to ECT 
[12]. We suspect that hyaline membrane disease and congenital 
hypertropic pyloric stenosis shown in this case were not related 
with ECT, but were not able to completely exclude in this 
possibility.
    Another survey of 318 pregnant women observed nine cases 
of premature labor caused by ECT [11]. We also found that 
uterine contraction appeared about 1 hour after the first session, 
and was controlled by ritodrine. In the next 6 sessions of ECT 
there was no episode of uterine contraction or other adverse 
events. Close monitoring of maternal and fetal conditions after 
cessation of ECT could have helped to detect adverse events 
probably caused by ECT in advance.
    Uterine contraction usually can be controlled by ritodrine or 
magnesium sulfate as in this case, and fetal bradyarrhythmias 
can be avoided by adequate preoxygenation and proper 
position of the mother to minimize aortocaval compression by 
elevating the right hip and displacing the uterus [12,13].
    Another anesthetic consideration in ECT for pregnancy 
is on regurgitation of gastric acid resulting from an upward 
displacement of the stomach and intestines by the enlarged 
uterus [9]. The simplest method to prevent aspiration is 
to apply constant manual pressure to the cricoid cartilage 
(Sellick’s maneuver). Patients in their third trimester should be 
considered for endotracheal intubation with ECT. We had the 
patient keep the NPO for more than 8 hours with fluid infusion 
and Sellick’s maneuver was applied during ECT.
    Although ECT typically has little effect on fetal and maternal 
status [14], the anesthesiologist also should be aware of the 
complications of the ECT. Tocodynamometry during ECT can 
be helpful for monitoring uterine activity and early detection of 
uterine contraction [15].
    This patient received a Cesarean-section due to aggravating 
psychotic symptoms. The baby was born prematurely with 
under-development of the pulmonary system and congenital 
hypertropic pyloric stenosis. This baby got the ventilatory care 
with surfactant treatment and pyloromyotomy.
    On first ECT application, uterine contraction was detected 
after 1 hour of ECT, which was well controlled with a tocolytic 
agent. In anesthetic care for ECT during pregnancy, monitoring 
of the mother and fetus for over 1 hour is important with airway 
management during ECT.
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